دورية أكاديمية
Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres.
العنوان: | Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. |
---|---|
المؤلفون: | Alzahrani M; Division of Hematology & Hematopoietic Stem Cell Transplantation, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia., Damlaj M; Division of Hematology & Hematopoietic Stem Cell Transplantation, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia., Jeffries N; Office of Biostatistics Research, National Heart, Lung, and Blood Institute, Bethesda, MD, USA., Alahmari B; Division of Hematology & Hematopoietic Stem Cell Transplantation, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia., Singh A; Division of Hematology/Oncology, University of Illinois Hospital and Health Science Systems, Chicago, IL, USA., Rondelli D; Division of Hematology/Oncology, University of Illinois Hospital and Health Science Systems, Chicago, IL, USA., Tisdale JF; Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA., Saraf SL; Division of Hematology/Oncology, University of Illinois Hospital and Health Science Systems, Chicago, IL, USA., Hsieh MM; Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA. |
المصدر: | British journal of haematology [Br J Haematol] 2021 Feb; Vol. 192 (4), pp. 761-768. Date of Electronic Publication: 2021 Feb 03. |
نوع المنشور: | Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural |
اللغة: | English |
بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Oxford : Wiley-Blackwell Original Publication: Oxford : Blackwell Scientific Publications |
مواضيع طبية MeSH: | HLA Antigens*/immunology , Hematopoietic Stem Cell Transplantation*/adverse effects , Hematopoietic Stem Cell Transplantation*/methods, Anemia, Sickle Cell/*therapy, Adolescent ; Adult ; Alemtuzumab/therapeutic use ; Anemia, Sickle Cell/immunology ; Antineoplastic Agents, Immunological/therapeutic use ; Child ; Female ; Graft Rejection/etiology ; Graft Rejection/immunology ; Graft Survival ; Graft vs Host Disease/etiology ; Graft vs Host Disease/immunology ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; Sirolimus/therapeutic use ; Tissue Donors ; Transplantation, Homologous/adverse effects ; Transplantation, Homologous/methods ; Treatment Outcome ; Young Adult |
مستخلص: | Non-myeloablative haematopoietic progenitor cell transplantation (HPCT) from matched related donors (MRD) has been increasingly utilized in sickle cell disease (SCD). A total of 122 patients received 300 cGy of total body irradiation (TBI), alemtuzumab, unmanipulated filgrastim-mobilized peripheral blood HPC and sirolimus. The median follow-up was four years; median age at HPCT was 29 years. Median neutrophil and platelet engraftment occurred on day 22 and 19 respectively; 41 patients required no platelet transfusions. Overall and sickle-free survival at one and five years were 93% and 85% respectively. Age, sex, pre-HPCT sickle complications, ferritin and infused HPC numbers were similar between graft failure and engrafted patients. Mean donor myeloid chimaerism at one and five years post HPCT were 84% and 88%, and CD3 was 48% and 53% respectively. Two patients developed grade 1 and 2 skin graft-versus-host disease (GVHD) with no chronic GVHD. Median days of recipients taking immunosuppression were 489; 83% of engrafted patients have discontinued immunosuppression. Haemoglobin, haemolytic parameters and hepatic iron levels improved post HPCT. Pulmonary function testing, hepatic histology and neurovascular imaging remained stable, suggesting cessation of further sickle-related injury. Fourteen patients had children. In this largest group of adult SCD patients, this regimen was highly efficacious, well-tolerated despite compromised organ functions pre HPCT, and without clinically significant GVHD. (© Published 2020. This article is a U.S Government work and is in the public domain in the USA.) |
التعليقات: | Comment in: Br J Haematol. 2021 Feb;192(4):678-680. (PMID: 33482009) |
References: | N Engl J Med. 2004 Feb 26;350(9):886-95. (PMID: 14985486) Leuk Lymphoma. 2018 Jan;59(1):241-244. (PMID: 28587497) Biol Blood Marrow Transplant. 2016 Mar;22(3):441-8. (PMID: 26348889) Blood. 2011 Aug 4;118(5):1197-207. (PMID: 21628400) Blood. 2018 Oct 25;132(17):1750-1760. (PMID: 30206116) Biol Blood Marrow Transplant. 2010 Feb;16(2):263-72. (PMID: 19822218) Blood. 2020 Apr 2;135(14):1185-1188. (PMID: 32062672) N Engl J Med. 2017 Mar 2;376(9):848-855. (PMID: 28249145) N Engl J Med. 2018 Jul 19;379(3):226-235. (PMID: 30021096) Blood Adv. 2020 May 12;4(9):2084-2094. (PMID: 32396620) Haematologica. 2017 Apr;102(4):626-636. (PMID: 28104703) N Engl J Med. 2009 Dec 10;361(24):2309-17. (PMID: 20007560) N Engl J Med. 2019 Aug 8;381(6):509-519. (PMID: 31199090) Aliment Pharmacol Ther. 2015 Oct;42(7):912-21. (PMID: 26235444) Lancet Haematol. 2019 Nov;6(11):e585-e596. (PMID: 31495699) Am J Hematol. 2015 Dec;90(12):1093-8. (PMID: 26348869) Am J Hematol. 2010 Jun;85(6):403-8. (PMID: 20513116) Blood. 2017 Mar 16;129(11):1548-1556. (PMID: 27965196) Am J Respir Crit Care Med. 2007 Jun 15;175(12):1272-9. (PMID: 17379852) Blood. 2017 Oct 26;130(17):1946-1948. (PMID: 28887325) N Engl J Med. 1984 Sep 20;311(12):780-3. (PMID: 6382010) JAMA Pediatr. 2020 Feb 1;174(2):195-197. (PMID: 31816036) Bone Marrow Transplant. 2001 Sep;28(5):511-8. (PMID: 11593326) Biol Blood Marrow Transplant. 2019 Jun;25(6):1197-1209. (PMID: 30500440) N Engl J Med. 1996 Aug 8;335(6):369-76. (PMID: 8663884) Am J Hematol. 2018 Sep;93(9):1153-1160. (PMID: 29981283) N Engl J Med. 2017 Feb 2;376(5):429-439. (PMID: 27959701) Am J Respir Crit Care Med. 2006 Jun 1;173(11):1264-9. (PMID: 16556694) JAMA. 2014 Jul 2;312(1):48-56. (PMID: 25058217) Medicine (Baltimore). 1996 Nov;75(6):300-26. (PMID: 8982148) Cytotherapy. 2019 Dec;21(12):1206-1215. (PMID: 31784240) JAMA. 2019 Jan 22;321(3):266-276. (PMID: 30667500) Am J Pediatr Hematol Oncol. 1994 Feb;16(1):18-21. (PMID: 8311167) Blood. 2015 Sep 24;126(13):1544-50. (PMID: 26261241) Blood. 2012 Nov 22;120(22):4285-91. (PMID: 22955919) Biol Blood Marrow Transplant. 2017 Dec;23(12):2178-2183. (PMID: 28882446) Blood Adv. 2019 Oct 8;3(19):2816-2824. (PMID: 31578191) Transplantation. 2005 Dec 15;80(11):1541-5. (PMID: 16371922) Haematologica. 2020 Jan;105(1):91-101. (PMID: 31097628) Biol Blood Marrow Transplant. 2019 Jun;25(6):1179-1186. (PMID: 30772511) |
معلومات مُعتمدة: | Z99 HL999999 United States ImNIH Intramural NIH HHS; HL006007-11 United States HL NHLBI NIH HHS |
فهرسة مساهمة: | Keywords: alemtuzumab; allogeneic transplantation; matched related donor; sickle cell disease; sirolimus |
المشرفين على المادة: | 0 (Antineoplastic Agents, Immunological) 0 (HLA Antigens) 0 (Immunosuppressive Agents) 3A189DH42V (Alemtuzumab) W36ZG6FT64 (Sirolimus) |
تواريخ الأحداث: | Date Created: 20210203 Date Completed: 20210615 Latest Revision: 20221005 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC8582053 |
DOI: | 10.1111/bjh.17311 |
PMID: | 33534948 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1365-2141 |
---|---|
DOI: | 10.1111/bjh.17311 |